Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Endonovo Therapeutics, Inc. (ENDV) Message Board

Fatty Livers is a condition that is becoming very

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 416
(Total Views: 1024)
Posted On: 09/23/2017 11:21:24 AM
Avatar
Posted By: CyberC
Fatty Livers is a condition that is becoming very common, and Endonovo is the Only biotech currently developing a non-invasive, non-pharmacological approach for the treatment of NASH, an inflammatory condition in the liver due to a buildup of fat that can lead to cirrhosis and liver failure if left untreated that can lead to liver failure.

If this study, or any of the other studies that are currently in process are completed this a high degree of success, we are in for one exciting ride. Consider the following:

This traded at .70 18 months ago w/ no trial results. It ran to .14 earlier this year....again w/ no news. I think a dollar or more is a conservative forecast w/ positive trial results. However, you have to keep in mind that once they prove the technology works on one trial, the likelihood that it works for many ailments is extremely probable. That being said a multiple dollars plus is definitely a possibility.

Don't be surprised if after the release of just one successful study we login to our trading account and find ENDV trading for $3.50 a share. It's happened to other stocks and it could happen here.


(0)
(0)




Endonovo Therapeutics, Inc. (ENDV) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  


WORDS TO LIVE BY:

Never argue with stupid people, they will drag you down to their level and then beat you with experience.


Get .... PrivacyLok https://cyberidguard.com/

Try SafeVchat: https://cyberidguard.com/

My comments are only my opinion and are not to be used for investment advice.

Please conduct your own due diligence before choosing to buy or sell any stock.

xgqbj600g2g.jpg




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us